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Diabetes type 1 is a chronic autoimmune disease in which insulin-producing cells are gradually destroyed by autoreactive T cells.
Human regulatory cells play important role in controlling autoimmunity, and their qualitative or quantitative dysfunctions may
result in ineﬀective suppression of autoreactive T cells. CD62L is a surface molecule that plays role in homing capabilities of
Tregs, and only cells with high expression of CD62L have high suppressive potential. Tregs are also characterized by the constant
expression of TNFR2. The frequency of Tregs carrying TNFR2 is higher in inﬂammatory conditions. We investigated blood
regulatory Tcells withCD62Lexpression andregulatory Tcellsexpressing TNFR2intype 1diabetic patients.Wefounddiﬀerences
in these populations when comparing to healthy individuals. We propose that these may be associated with inﬂammatory
conditions that are present in patients with type 1 diabetes. The lower percentage of Tregs and Treg CD62Lhigh may contribute
to ineﬀective suppression of proinﬂammatorycytokines production during type 1 diabetes.
1.Introduction
Diabetes type 1 is a chronic autoimmune disease that is
characterized by the destruction of insulin-producing cells.
It has been shown that this disorder involves failure in
immune regulation [1, 2]. NOD mice and patients with type
1 diabetes have deﬁciencies in at least two T-cell populations
with regulatory properties: NKT and CD4+CD25+ [3–5].
Human CD4+CD25+ regulatory T cells, that are character-
ized by high expression of CD25 molecule-comprise 5–10%
of peripheral CD4+ T cells [6, 7] and are characterized by
the upregulation of the IL-2receptor alfa-chain (CD25) and
expression of the transcription factor Foxp3 [8, 9]. Some
data suggest that regulatory T cells are most eﬀective in
preventing priming of naive cells [10]. This requires their
presence in lymph nodes. The receptor that homes to lymph
nodes is CD62L molecule (L-selectin). Lower expression of
CD62L was observed on CD3+ lymphocytes from diabetic
type 1 patients in comparison to their healthy counterparts
[11].Inaddition,thelowpercentageofCD4+CD25+CD62L+
and their poor eﬃcacy in preventing autoimmunity was
observed in NOD mouse [12–15]. Another surface molecule
which seems to be important for regulatory T cells is the
TNF receptor type 2 (TNFR2). Its constant expression was
observed on Tregs [16, 17]. It was also shown that exposure
to TNF enhanced the percentage of Tregs expressing TNFR2
and downmodulated their suppressive activity at the same
time [17]. Chronic inﬂammation present in autoimmune
environment may impair the number and/or function of
Tregs, which then are not able to prevent the activity of
inﬂammatory cells. As inﬂammation proceeds, the risk for
vascular complications increases [18, 19].
Here, we demonstrate that patients with type 1 diabetes
have lower percentage of peripheral blood regulatory T cells
with CD62L expression and higher percentage of regula-
tory T cells expressing TNFR2 than healthy individuals.2 Mediators of Inﬂammation
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Figure 1: Gating strategy used to analyze CD4+CD25high regulatory Tcells in peripheral blood.Thewholebloodwasstainedwithantibodies
against Treg cell surface molecules. Sample gated on lymphocytes according to forward and side scatter (FSC/SSC) (a). Plots showing gate
for CD4+ T cells (b) and CD4+CD25high cells (c). Cells in CD4+CD25high gate gated on TNFR2+ (d) and CD62Lhigh cells (e).
We propose that these diﬀerences may be associated with
inﬂammatory conditions that are present in patients with
type 1 diabetes.
2.MaterialandMethods
2.1. Patients. 35 patients aged 15.5 (±3.2) years with long-
standing diabetes type 1 and 20 age-matched (19.8 ± 1.2
years) healthy individuals had fresh blood samples collected
for analysis. The mean duration of diabetes was 6.45
(±3.7) years. The patients were recruited from The Diabetic
Department, Clinic of Pediatrics, Hematology, Oncology
and Endocrinology, Medical University of Gda´ nsk. Type
1 diabetes was deﬁned according to the criteria of the
American Diabetes Association [20]. A blood glucose level
was taken at the time of sampling along with biochemical
measurement of renal function, lipid status, CRP, and glyco-
sylated hemoglobin (HbA1c). At each examination, systolic
and diastolic blood pressure was measured. The study
followed the principles of the Declaration of Helsinki andMediators of Inﬂammation 3
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Figure2:ExpressionofCD62LandTNFR2deﬁnedasmeanﬂuorescenceintensityindiabetictype1patientsandhealthyindividuals.During
cytometric analysis of peripheral blood CD4+CD25high T cells, the mean ﬂuorescent intensity of CD62L and TNFR2 was deﬁned. The MFI
of CD62L in CD4+CD25highCD62Lhigh gate in diabetic group was 22.34 (15.91/26.6) and 37.7 (29.8/57.5) in control group (P = .0001). The
MFI of TNFR2 in CD4+CD25highTNFR2+ gate was 5.66 (4.52/7.83) in DM1 group and 3.96 (2.32/5.37) in the control group (P = .0004).
The data are presented as median and 10th percentile/90th percentile. The diﬀerences were calculated by U-Mann Whitney test.
was approved by The Ethics Committee of The Medical
University of Gda´ nsk. Clinical characteristics of the patients
are presented in Table 1.
2.2. Flow Cytometric Analysis. Blood samples (50μL) were
stained with anti-CD4 (IgG1, κ mouse Pe/Cy5, Clone RPA-
T4, BioLegend, USA), anti-CD25 (IgG1, κ mouse FITC,
Clone BC96, BioLegend, USA), anti-TNFR2 (IgG2A mouse
PE, Clone: 22235, R&D Systems Inc, USA), and anti-CD62L
(IgG1, κ mouse APC, Clone DREG-56, BioLegend, USA)
human antibodies. For each set, appropriate isotypic control
was done. After 30-minute incubation in the dark at a room
temperature, probes were ﬁxed using Immunoprep reagents
(Immunotech, USA)with Q-prep Immunology Workstation
(Coulter, USA).
Expression of cell surface and intracellular markers was
assessed using ﬂow cytometry (LSRII, Becton Dickinson,
USA) after gating on live cells determined by scatter
characteristics. Data were analyzed by FACSDiva 6.0 Soft-
ware (Becton Dickinson, USA). The expression of CD62L
in the CD4+CD25highCD62Lhigh as well as expression of
TNFR2 in the CD4+CD25highTNFR2+gates were quantiﬁed
by determining mean ﬂuorescent intensity (MFI). Figure 1
shows gating strategy used for analysis of regulatory T-cell
subsets.
2.3. Determination of TNF Level. Serum level of TNF was
measured by immunoenzymatic ELISA method (Quantikine
High Sensitivity Human by R&D Systems Inc, USA) accord-
ing to the manufacturer protocol. Minimum detectable
concentrations were determined by the manufacturer as
0.12pg/mL.
Table 1: Clinical characteristics of patients with type 1 diabetes.
Clinical parameter Mean ± Standard deviation
Age (years) 15.5 ±3.2
Duration of diabetes (years) 6.45 ±3.7
BMI 19.9 ±3.43
CRP (mg/L) 3.62 ±1.24
HbA1c (%) 10.1 ±2.8
Systolic blood pressure (mmHg) 116.0 ±14.6
Diastolic blood pressure (mmHg) 74.0 ±10.0
Serum creatinine level (mg/dL) 0.74 ±0.15
Serum albumin level (g/L) 19.85 ±12.16
Data are shown as mean ± standard deviation.
2.4. Statistical Analysis. All statistical analyses were per-
formed using Statistica 8.0 (StatSoft, Inc USA).
The diﬀerences between the groups were calculated with
the nonparametric U-Mann Whitney tests. Multiple regres-
sion analysis was performed to determine if CD4+CD25high
T cell level depends on age and disease duration in diabetic
group. Spearman’s correlations were used to compare cell
frequencies with analyzed parameters. P values less than.05
were considered statistically signiﬁcant.
3.Results
3.1. Peripheral Blood CD4+CD25high,C D 4 +CD25high
CD62Lhigh,a n dC D 4 +CD25highTNFR2+ T Cells. The multi-
ple regression analysis showed no association between
the peripheral blood level of CD4+CD25high regulatory T
cells and age as well as disease duration in diabetic group
(β = [−0.04] and [−0.37], resp., P = .2).4 Mediators of Inﬂammation
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Figure 3: Relationship between CD4+CD25high regulatory T-cells, their subpopulations frequencies, and HbA1c level in analyzed DM1
subjects. The level of HbA1c was measured in the blood of DM1 children and correlated with the percentage of peripheral blood regulatory
T-cell subpopulations. The Spearman test was used to calculate the strength of correlation. (a) The correlation between CD4+CD25high
frequency andHbA1c level in DM1 subjects (r = [−0.32]);(b) the correlation between CD4+CD25highCD62Lhigh frequency andHbA1c level
in DM1 subjects (r = [−0.33]); (c) the correlation between CD4+CD25highTNFR2+ frequency and HbA1c level in DM1 subjects (r = 0.46).
∗The percentage of cells among peripheral blood lymphocytes, ∗∗the percentage of cells among CD4+CD25high lymphocytes.
Children with type 1 diabetes were characterized by
lower number and percentage of the CD4+CD25high T cells
(Table 2, P = .00084, P = .00026), lower number and
percentage of the CD4+CD25highCD62Lhigh (Table 2, P =
.00012, P = .0000) than their healthy counterparts. When
numbers of the CD4+CD25highTNFR2+ T cells were com-
pared, the opposite eﬀect was revealed. Tregs expressing
TNFR2were morefrequentinDM1group;however,thiswas
true onlywhen the percentageofcellswas takeninto account
(Table 2, P = .0000).
As to the expression of CD62L and TNFR2 in
CD4+CD25highCD62Lhigh and CD4+CD25highTNFR2+ cells,
respectively, ﬂow cytometric analysis indicated that there
was a signiﬁcant diﬀerence in the MFI of these molecules
between analyzed groups. The expression of CD62L was
higher in control group (Figure 2, P = .0001), while
theexpressionofTNFR2washigherinDM1group(Figure 2,
P = .0004).
3.2. The Association between the Percentage of Treg Subsets
and Clinical Parameters in DM1 Group. In DM1 group,
the association analysis correlating HbA1c and CRP levels
versus the CD4+CD25high and their subpopulations fre-
quency was performed (Figures 3 and 4). In the study
group, the level of HbA1c was in signiﬁcant relation with
the frequency of CD4+CD25high (r = [−0.3]; P<. 05)
CD4+CD25highCD62Lhigh (r = [−0.33]; P<. 05) as well as
CD4+CD25highTNFR2+(r = 0.46; P<. 05). The signiﬁcantly
negative correlation was also found between CRP level and
the frequency of CD4+CD25high (r = [−0.69]; P<. 05)
as well as CD4+CD25highCD62Lhigh (r = [−0.064]; P<
.05).Mediators of Inﬂammation 5
Table 2: The percentage and number of CD4+CD25high,C D 4 +CD25highCD62Lhigh,a n dC D 4 +CD25highTNFR2+ T cells.
Children with DM1 Control group P
(n = 35) (n = 20)
The percentage of CD4+CD25high cells (%)∗ 1.56 (0.4/4.6) 3.30 (2.5/4.9) .00026
The absolute number of CD4+CD25high (cells/mm3) 0.37 (0.03/4.17) 1.13 (0.55/2.21) .00084
The percentage of CD4+CD25high CD62Lhighcells (%)∗∗ 54.3 (20.0/79.2) 90.2 (76.4/94.3) .00000
The absolute number of CD4+CD25high CD62Lhigh cells (cells/mm3) 0.014 (0.02/2.76) 1.01 (0.48/2.08) .000012
The percentage of CD4+CD25highTNFR2+cells (%)∗∗ 96.9 (85.7/99.8) 34.95 (21.6/46.0) .0000
The absolute number of CD4+CD25highTNFR2+cells (cells/mm3) 0.27 (0.03/4.158) 0.4 (0.11/1.08) .26
Results are shown as median and 10th percentile/90th percentile. All the diﬀerences were calculated by the U-Mann Whitney test.
∗The percentage of cells among peripheral blood lymphocytes.
∗∗The percentage of cells among CD4+CD25high lymphocytes.
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Figure4:Relationshipbetween CD4+CD25high regulatory Tcells,theirsubpopulationsfrequencies,andCRPlevelinanalyzedDM1subjects.
Thelevel ofC-reactive protein wasmeasuredin thebloodofDM1 children andcorrelated withthepercentage ofperipheral bloodregulatory
T-cell subpopulations. The Spearman test was used to calculate the strength of correlation. (a) The correlation between CD4+CD25high
frequency and CRP level in DM1 subjects (r = [−0.69]); (b) the correlation between CD4+CD25highCD62Lhigh frequency and CRP level in
DM1 subjects (r = [−0.64]);(c) the correlation between CD4+CD25highTNFR2+ frequency and CRP level in DM1 subjects (r = 0.36). ∗The
percentage of cells among peripheral blood lymphocytes, ∗∗the percentage of cells among CD4+CD25high lymphocytes.6 Mediators of Inﬂammation
3.3. The Relationship between CD4+CD25high Regulatory T-
Cell Subpopulation Frequencies and Serum TNF Level in
Diabetic Type 1 Children. We then studied the association
betweenserumlevelofTNFand thepercentageofperipheral
blood regulatory T cells in analyzed DM1 subjects. We
found that diabetic type 1 children with higher percentage
of CD4+CD25highTNFR2+ cells among peripheral blood
CD4+CD25high had higher serum level of TNF (Figure 5,
r = 0.53; P<. 05). When analyzing CD4+CD25high and
CD4+CD25highCD62Lhigh subpopulations, we did not ﬁnd
any association between frequency of these cells and TNF
serum level.
4.Discussion
Some authors have previously suggested that patients with
type 1 diabetes have lower frequency of regulatory T cells
in peripheral blood [5, 21]. Our work clearly revealed
that children with type 1 diabetes are characterized by
lower percentage and absolute number of CD4+CD25high
regulatory T cells as compared with age-matched healthy
individuals. These quantitative defects may be caused by
the chronic inﬂammation, which is observed in diabetic
type 1 patients [18, 19, 22] and was observed in our study
group. The analyzed patients had high serum level of CRP
and detectable level of TNF, which are indicators of chronic
inﬂammatory response [18, 19, 22]. The strong correlation
was observed in our study group; patients with lower CRP
level had higher percentage of CD4+CD25high cells among
peripheralbloodlymphocytesthanpatientswith higherCRP
level.
Some data concerning regulatory T cells have shown that
these cells are susceptible to the eﬀects mediated by the
proinﬂammatory cytokine—TNF [23], which may impair
their activity through TNFR2 signalization [17].Our results
are consistent with the ﬁndings of Valencia et al., who
demonstrated that CD4+CD25high T r e g sf r o mp a t i e n t sw i t h
activeRAcontainedgreaterpercentageofTNFR2+ cellscom-
pared with healthy controls [17]. Our studies gave similar
results showing that the CD4+CD25highTNFR2+ T cells from
DM1 patients had higher expression of TNFR2 than cells
from the control group. Moreover, our studies revealed the
correlation between percentage of CD4+CD25highTNFR2+
lymphocytes and serum level of HbA1c as well as CRP.
Patients with poor metabolic control and higher CRP level
had higher percentage of Tregs carrying TNFR2. These
patients also produced more TNF than those with lower
percentage of regulatory T cells expressing TNFR2. The
observed greater CD4+CD25highTNFR2+ frequency in DM1
patients may reﬂect the greater sensitivity of this cell subset
to inﬂammatory conditions and the action of TNF.
I nv i e wo ft h ef a c tt h a ti nc a s eo fd i a b e t e so n l ys u b -
population of Tregs that carries CD62L has high suppressive
activity [13, 15], we can suspect that the lower percentage of
CD4+CD25highCD62Lhighcells among peripheral blood Tregs
as well as the expression of CD62L on CD62Lhigh Tregs in
DM1 group may be associated with defect in the homing
capabilities of this cell population, as CD62L is responsible
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Figure 5: Relationship between the percentage of
CD4+CD25highTNFR2+ regulatory T cells and serum TNF level in
analyzed DM1 subjects. The level of TNF was measured in serum
of diabetic type 1 patients and correlated with the percentage
of peripheral blood regulatory T cells carrying TNFR2 in these
patients. The Spearman test was used to calculate the strength of
correlation (r = 0.5; P<. 05). ∗∗The percentage of cells among
CD4+CD25high lymphocytes.
for migration ofTregs to secondary lymphoidtissues [13].In
addition, when analyzing CD4+CD25highCD62Lhigh subset,
we found that patients with lower percentage of these
cells had higher serum CRP level, in which elevated level
may reﬂect an inﬂammatory state [24]. They also had
higher HbA1c level which is an indicator of metabolic
control in diabetic patients [25]. Higher HbA1c is associated
with higher serum TNF level [26, 27], so more intense
inﬂammatory response. This may further cause disruption
in regulatory T-cell population. The lower numbers of
CD62Lhigh Treg subpopulation in type 1 diabetic patients
give weight to the importance of regulatory T-cell migration
to secondary lymphoid tissues in order to control activity of
inﬂammatory cells.
Theinﬂammatory conditionsseeninpatientswith type1
diabetes may modulate Treg subsets, such that they are not
able to control inﬂammation. Further studies are needed to
determine the suppressive activity of these cells in order to
see if their function is disrupted.
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